Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epstein-Barr virus induced adoptive T-cell therapy - Eutilex

Next Previous
X
Search
Drug Profile

Epstein-Barr virus induced adoptive T-cell therapy - Eutilex

Alternative Names: EBV-induced Natural T cell; EBViNT

Latest Information Update: 25 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eutilex
  • Class Cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II T-cell lymphoma

Most Recent Events

  • 15 Mar 2021 Phase I/II clinical trials is still ongoing in T-cell lymphoma (Second-line therapy or greater) in South Korea (IV) (Eutilex pipeline, March 2021)
  • 14 Dec 2018 Phase-I/II clinical trials in T-cell lymphoma (Second-line therapy or greater) in South Korea (IV) (NCT03789617)
  • 03 Oct 2018 Phase I development is ongoing in South Korea (Eutilex pipeline, October 2018)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top